论文部分内容阅读
为确定脑瘤的磁化传递(MT)半剂量增强MRI能否替代非磁化传递的标准剂量增强MRI,作者用该技术在1.0T或1.5 T场强条件下对25例患者共32个经组织证实的颅内肿瘤进行前瞻性研究。男8例,女17例,15～70岁,其中转移瘤8个,胶质瘤7个,脑膜瘤6个,淋巴瘤、脉络丛乳头状瘤、垂体腺瘤、神经鞘瘤各2个,血管母细胞瘤、颅咽管瘤及未能确定的脑内肿瘤各1个。SE序列矢状位T_1WI、横断面T_2WI平扫后,在多平面行SE序列标准剂量Gd-DTPA(0.1mmol/kg)增强T_1WI。一周内,每例患者静脉注射半剂量Gd-DTPA(0.05mmol/kg)分别行SE序列MT和非MT T_1WI。两
To determine whether MR imaging of magnetic resonance transmission (MT) of brain tumors could replace non-magnetization-delivered standard-dose-contrast MRI, the authors used this technique to validate a total of 32 of 25 patients at 1.0T or 1.5T field strength The intracranial tumors were prospectively studied. 8 males and 17 females, 15 to 70 years old, of which 8 were metastases, 7 gliomas, 6 meningioma, 2 lymphoma, choroid plexus papilloma, 2 pituitary adenomas, Hemangioblastoma, craniopharyngioma, and undetermined brain tumor each one. SE sequence of sagittal T_1WI, transverse plane T_2WI after plain scan, in the multiplanar row SE sequence standard dose Gd-DTPA (0.1mmol / kg) enhanced T_1WI. Within one week, each patient received a single intravenous dose of Gd-DTPA (0.05 mmol / kg), respectively, SE sequence MT and non-MT T_1WI. Two